By proceeding, you agree to our Terms of Use and Privacy Policy.
Peter Schafer is Scientific Vice President at Bristol Myers Squibb
Talks About #DrugDiscovery #Biotechnology
Preferred Locations #NorthAmerica
With two approved therapeutics and the field working to develop the next generation of IPF drugs, the opportunity to become the undisputed, most effective, and disease-modifying agent on the market has never been greater.